Kaseta Michael 4

What Happened
Michael Kaseta, a director of Heron Therapeutics (HRTX), was granted 53,960 restricted stock units (RSUs) on January 30, 2026. The Form 4 reports the award at an acquisition price of $0.00 (standard for RSU grants); the units are a contingent right to receive common shares if vested. This is a compensation award (grant), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-30 (Filed on 2026-02-03; filing appears timely — within required two business days).
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 53,960 RSUs at $0.00 per unit.
• Vesting: RSUs vest in full on January 30, 2027 (per footnote). Each RSU represents a contingent right to one share of common stock.
• Shares owned after transaction: Not disclosed in this Form 4.
• No tax withholding, 10b5-1 plan, or sale details are reported in this filing.

Context
RSU grants are common director/executive compensation and do not constitute an immediate purchase or sale — the recipient only receives actual shares if/when the RSUs vest (and any forfeiture or service conditions are satisfied). Such awards are informative about compensation policy but do not by themselves indicate insider buying or selling intent.